Search tips
Search criteria 


Logo of envhperEnvironmental Health PerspectivesBrowse ArticlesAbout EHPGeneral InformationAuthorsMediaProgramsPartnerships
Environ Health Perspect. 1998 August; 106(Suppl 4): 1047–1050.
PMCID: PMC1533320
Research Article

Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population.


Ingestion of arsenic-contaminated drinking water is associated with an increased risk of several cancers, including skin and bladder malignancies; but it is not yet clear whether such adverse effects are present at levels to which the U.S. population is exposed. In New Hampshire, detectable levels of arsenic have been reported in drinking water supplies throughout the state. Therefore, we have begun a population-based epidemiologic case-control study in which residents of New Hampshire diagnosed with primary squamous cell (n = 900) and basal cell (n = 1200) skin cancers are being selected from a special statewide skin cancer incidence survey; patients diagnosed with primary bladder cancers (n = 450) are being identified through the New Hampshire State Cancer Registry. Exposure histories of these patients will be compared to a control group of individuals randomly selected from population lists (n = 1200). Along with a detailed personal interview, arsenic and other trace elements are being measured in toenail clipping samples using instrumental neutron activation analysis. Household water samples are being tested on selected participants using a hydride generation technique with high-resolution inductively coupled plasma mass spectrometry. In the first 793 households tested arsenic concentrations ranged from undetectable (0.01 microgram/l) to 180 microgram/l. Over 10% of the private wells contained levels above 10 microgram/l and 2.5% were above 50 microgram/l. Based on our projected sample size, we expect at least 80% power to detect a 2-fold risk of basal cell or squamous cell skin cancer or bladder cancer among individuals with the highest 5% toenail concentrations of arsenic.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (946K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Tseng WP, Chu HM, How SW, Fong JM, Lin CS, Yeh S. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst. 1968 Mar;40(3):453–463. [PubMed]
  • Brown KG, Boyle KE, Chen CW, Gibb HJ. A dose-response analysis of skin cancer from inorganic arsenic in drinking water. Risk Anal. 1989 Dec;9(4):519–528. [PubMed]
  • Smith AH, Hopenhayn-Rich C, Bates MN, Goeden HM, Hertz-Picciotto I, Duggan HM, Wood R, Kosnett MJ, Smith MT. Cancer risks from arsenic in drinking water. Environ Health Perspect. 1992 Jul;97:259–267. [PMC free article] [PubMed]
  • Bates MN, Smith AH, Cantor KP. Case-control study of bladder cancer and arsenic in drinking water. Am J Epidemiol. 1995 Mar 15;141(6):523–530. [PubMed]
  • Morton W, Starr G, Pohl D, Stoner J, Wagner S, Weswig D. Skin cancer and water arsenic in Lane County, Oregon. Cancer. 1976 May;37(5):2523–2532. [PubMed]
  • Berg JW, Burbank F. Correlations between carcinogenic trace metals in water supplies and cancer mortality. Ann N Y Acad Sci. 1972 Jun 28;199:249–264. [PubMed]
  • Armstrong BK, Kricker A. Skin cancer. Dermatol Clin. 1995 Jul;13(3):583–594. [PubMed]
  • Yeh S, How SW, Lin CS. Arsenical cancer of skin. Histologic study with special reference to Bowen's disease. Cancer. 1968 Feb;21(2):312–339. [PubMed]
  • Brown LM, Zahm SH, Hoover RN, Fraumeni JF., Jr High bladder cancer mortality in rural New England (United States): an etiologic study. Cancer Causes Control. 1995 Jul;6(4):361–368. [PubMed]
  • Hsueh YM, Chiou HY, Huang YL, Wu WL, Huang CC, Yang MH, Lue LC, Chen GS, Chen CJ. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):589–596. [PubMed]
  • Garland M, Morris JS, Rosner BA, Stampfer MJ, Spate VL, Baskett CJ, Willett WC, Hunter DJ. Toenail trace element levels as biomarkers: reproducibility over a 6-year period. Cancer Epidemiol Biomarkers Prev. 1993 Sep-Oct;2(5):493–497. [PubMed]
  • Karagas MR, Morris JS, Weiss JE, Spate V, Baskett C, Greenberg ER. Toenail samples as an indicator of drinking water arsenic exposure. Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):849–852. [PubMed]
  • Chiou HY, Hsueh YM, Hsieh LL, Hsu LI, Hsu YH, Hsieh FI, Wei ML, Chen HC, Yang HT, Leu LC, et al. Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutat Res. 1997 Jun;386(3):197–207. [PubMed]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Science